Oncology firm Yellowstone Biosciences has chosen the ARC Oxford science campus as its first home.
The firm was spun out of the University of Oxford in June with support from Oxford University Innovation. It has launched with £16.5m secured in Series A funding, led by Syncona, to pioneer soluble bispecific TCR-based therapies for cancer.
The newly formed company has taken 8,152 sq ft of fully fitted CL2 lab and office space at Building 4100 at ARC Oxford – the entirety of the premises.
ARC Oxford is an innovation campus with ambitious growth plans to double the current 514,000 sq ft of space through the development of new laboratories, clean rooms, offices and research and development facilities.
Yellowstone Biosciences will join more than 35 science and technology occupiers at ARC Oxford, including Oxford Biomedica, MiroBio and OMass Therapeutics.
David Williams, senior director of leasing at ARC, said: “Given the rapid pace of growth of research-intensive businesses in Oxford and spin-outs from Oxford’s universities, it is crucial that we deliver a consistent, diverse and flexible supply of laboratory and technical space, to support both established companies and those in their infancy.”
Image © ARC
Send feedback to Evelina Grecenko
Follow Estates Gazette
